JP7696909B2 - ヘルペスウイルス糖タンパク質ｄと融合したｂ型肝炎ウイルス抗原をコードするアデノウイルスベクター及びその使用方法 - Google Patents

ヘルペスウイルス糖タンパク質ｄと融合したｂ型肝炎ウイルス抗原をコードするアデノウイルスベクター及びその使用方法 Download PDF

Info

Publication number
JP7696909B2
JP7696909B2 JP2022542413A JP2022542413A JP7696909B2 JP 7696909 B2 JP7696909 B2 JP 7696909B2 JP 2022542413 A JP2022542413 A JP 2022542413A JP 2022542413 A JP2022542413 A JP 2022542413A JP 7696909 B2 JP7696909 B2 JP 7696909B2
Authority
JP
Japan
Prior art keywords
seq
acid sequence
amino acid
nucleic acid
hbv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022542413A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021142212A5 (https=
JP2023510544A (ja
JP2023510544A5 (https=
Inventor
シージェイ アートル ヒルデガンド
スティーブン マゴワン コリン
Original Assignee
ビリオン セラピューティクス，リミティド ライアビリティ カンパニー
ザ ウィスター インスティテュート オブ アナトミー アンド バイオロジー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ビリオン セラピューティクス，リミティド ライアビリティ カンパニー, ザ ウィスター インスティテュート オブ アナトミー アンド バイオロジー filed Critical ビリオン セラピューティクス，リミティド ライアビリティ カンパニー
Publication of JP2023510544A publication Critical patent/JP2023510544A/ja
Publication of JPWO2021142212A5 publication Critical patent/JPWO2021142212A5/ja
Publication of JP2023510544A5 publication Critical patent/JP2023510544A5/ja
Priority to JP2025097871A priority Critical patent/JP2025124904A/ja
Application granted granted Critical
Publication of JP7696909B2 publication Critical patent/JP7696909B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2022542413A 2020-01-09 2021-01-08 ヘルペスウイルス糖タンパク質ｄと融合したｂ型肝炎ウイルス抗原をコードするアデノウイルスベクター及びその使用方法 Active JP7696909B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025097871A JP2025124904A (ja) 2020-01-09 2025-06-11 ヘルペスウイルス糖タンパク質ｄと融合したｂ型肝炎ウイルス抗原をコードするアデノウイルスベクター及びその使用方法

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US202062958809P 2020-01-09 2020-01-09
US202062958827P 2020-01-09 2020-01-09
US62/958,809 2020-01-09
US62/958,827 2020-01-09
US202062967242P 2020-01-29 2020-01-29
US202062967104P 2020-01-29 2020-01-29
US62/967,242 2020-01-29
US62/967,104 2020-01-29
US202063064506P 2020-08-12 2020-08-12
US202063064571P 2020-08-12 2020-08-12
US63/064,506 2020-08-12
US63/064,571 2020-08-12
US202063112202P 2020-11-11 2020-11-11
US202063112219P 2020-11-11 2020-11-11
US63/112,219 2020-11-11
US63/112,202 2020-11-11
PCT/US2021/012630 WO2021142212A1 (en) 2020-01-09 2021-01-08 Adenoviral vectors encoding hepatitis b viral antigens fused to herpes virus glycoprotein d and methods of using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025097871A Division JP2025124904A (ja) 2020-01-09 2025-06-11 ヘルペスウイルス糖タンパク質ｄと融合したｂ型肝炎ウイルス抗原をコードするアデノウイルスベクター及びその使用方法

Publications (4)

Publication Number Publication Date
JP2023510544A JP2023510544A (ja) 2023-03-14
JPWO2021142212A5 JPWO2021142212A5 (https=) 2023-10-31
JP2023510544A5 JP2023510544A5 (https=) 2023-10-31
JP7696909B2 true JP7696909B2 (ja) 2025-06-23

Family

ID=74505354

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022542413A Active JP7696909B2 (ja) 2020-01-09 2021-01-08 ヘルペスウイルス糖タンパク質ｄと融合したｂ型肝炎ウイルス抗原をコードするアデノウイルスベクター及びその使用方法
JP2025097871A Pending JP2025124904A (ja) 2020-01-09 2025-06-11 ヘルペスウイルス糖タンパク質ｄと融合したｂ型肝炎ウイルス抗原をコードするアデノウイルスベクター及びその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025097871A Pending JP2025124904A (ja) 2020-01-09 2025-06-11 ヘルペスウイルス糖タンパク質ｄと融合したｂ型肝炎ウイルス抗原をコードするアデノウイルスベクター及びその使用方法

Country Status (13)

Country Link
US (5) US12605444B2 (https=)
EP (1) EP4087605A1 (https=)
JP (2) JP7696909B2 (https=)
KR (1) KR20220163354A (https=)
CN (2) CN115335076B (https=)
AU (1) AU2021205936A1 (https=)
BR (1) BR112022013620A2 (https=)
CA (1) CA3166989A1 (https=)
IL (1) IL294387A (https=)
MX (1) MX2022008572A (https=)
PH (1) PH12022551648A1 (https=)
WO (1) WO2021142212A1 (https=)
ZA (1) ZA202310905B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL294387A (en) * 2020-01-09 2022-08-01 Virion Therapeutics Llc Adenovirus vectors encoding hepatitis b virus antigens fused to herpesvirus glycoprotein d and methods of using them

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070054262A1 (en) 2003-03-28 2007-03-08 Baker Denise M Methods of identifying optimal variants of peptide epitopes
JP2014507144A (ja) 2011-02-12 2014-03-27 グローブイミューン，インコーポレイテッド 慢性ｂ型肝炎感染症のための酵母系治療薬

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090246220A1 (en) * 2006-08-28 2009-10-01 Ertl Hildegund C J Constructs for enhancing immune responses
GB201223386D0 (en) * 2012-12-24 2013-02-06 Immune Targeting Systems Its Ltd Vaccine
EP2959915A1 (en) * 2014-06-23 2015-12-30 Institut Pasteur A dengue virus chimeric polyepitope composed of fragments of non-structural proteins and its use in an immunogenic composition against dengue virus infection
CN105367662B (zh) * 2014-08-29 2021-03-12 汤正好 一种hbv相关的融合蛋白、其制备方法及其应用
US11324819B2 (en) 2016-04-06 2022-05-10 University Of Washington Therapeutic vaccine for Hepatitis b virus (HBV) using the HBV core antigen
SG11201900808SA (en) 2016-08-01 2019-02-27 Wistar Inst Compositions and methods of replication deficient adenoviral vectors for vaccine applications
CN119770638A (zh) * 2019-09-30 2025-04-08 吉利德科学公司 Hbv疫苗和治疗hbv的方法
IL294387A (en) * 2020-01-09 2022-08-01 Virion Therapeutics Llc Adenovirus vectors encoding hepatitis b virus antigens fused to herpesvirus glycoprotein d and methods of using them

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070054262A1 (en) 2003-03-28 2007-03-08 Baker Denise M Methods of identifying optimal variants of peptide epitopes
JP2014507144A (ja) 2011-02-12 2014-03-27 グローブイミューン，インコーポレイテッド 慢性ｂ型肝炎感染症のための酵母系治療薬

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Vaccine，1993年，Vol.11, No.12，pp.1191-1198

Also Published As

Publication number Publication date
KR20220163354A (ko) 2022-12-09
JP2025124904A (ja) 2025-08-26
US12605444B2 (en) 2026-04-21
CN121221754A (zh) 2025-12-30
CN115335076B (zh) 2025-10-28
IL294387A (en) 2022-08-01
JP2023510544A (ja) 2023-03-14
CA3166989A1 (en) 2021-07-15
US20220175913A1 (en) 2022-06-09
US11291716B2 (en) 2022-04-05
BR112022013620A2 (pt) 2022-09-13
ZA202310905B (en) 2025-06-25
US11850282B2 (en) 2023-12-26
US20240091347A1 (en) 2024-03-21
US20250228934A1 (en) 2025-07-17
EP4087605A1 (en) 2022-11-16
US20230063089A1 (en) 2023-03-02
CN115335076A (zh) 2022-11-11
US12290561B2 (en) 2025-05-06
WO2021142212A1 (en) 2021-07-15
PH12022551648A1 (en) 2024-02-12
MX2022008572A (es) 2022-09-23
AU2021205936A1 (en) 2022-07-21
US20210393770A1 (en) 2021-12-23

Similar Documents

Publication Publication Date Title
US20230330215A1 (en) Sars-cov-2 vaccines
JP2020518648A (ja) アルファウイルス新生抗原ベクター
CN115948467A (zh) 针对乙型肝炎病毒的疫苗
CN114340661A (zh) Hiv抗原和mhc复合物
CN115942942A (zh) 感染性疾病抗原和疫苗
JP2025124904A (ja) ヘルペスウイルス糖タンパク質ｄと融合したｂ型肝炎ウイルス抗原をコードするアデノウイルスベクター及びその使用方法
Ragonnaud et al. Therapeutic vaccine against primate papillomavirus infections of the cervix
Dhalech et al. Coxsackievirus B3 elicits a sex-specific CD8+ T cell response which protects female mice
US20250121052A1 (en) Sars-cov-2 vaccines
Tan et al. Qualitative differences in cellular immunogenicity elicited by hepatitis C virus T-Cell vaccines employing prime-boost regimens
HK40082959A (en) Adenoviral vectors encoding hepatitis b viral antigens fused to herpes virus glycoprotein d and methods of using the same
US20240238412A1 (en) Pancoronavirus vaccines
WO2025199501A1 (en) Human papillomavirus (hpv) vaccines
CN118302195A (zh) 泛冠状病毒疫苗
JP2008508890A (ja) 組換え生鶏痘ウィルスベクター及びｃ型肝炎ウィルスに対する薬剤組成物中でのそれらの使用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231023

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231023

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241001

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250327

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250513

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250611

R150 Certificate of patent or registration of utility model

Ref document number: 7696909

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150